PetMed Express (PETS) Fundamentals 2026 — Revenue Analysis | SniperIQ
PetMed Express (PETS) is a US-listed Consumer Cyclical company in Specialty Retail with a market capitalization of $42M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PetMed Express's market cap?
PetMed Express (PETS) has a market capitalization of approximately $42M, trading at
What is PetMed Express's P/E ratio?
PetMed Express's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is PetMed Express?
PetMed Express runs a net profit margin of -32.0%, a gross margin of 22.8%, and an operating margin of -17.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PetMed Express generate?
PetMed Express reported revenue of
Does PetMed Express pay a dividend?
PetMed Express does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PetMed Express financially healthy?
PetMed Express carries a debt-to-equity ratio of 0.02x and a current ratio of 0.84x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PetMed Express a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PetMed Express (PETS) the key facts are: market cap $42M, revenue
Track PetMed Express's full fundamentals live
Get PetMed Express's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.